secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alkermes plc. (ALKS)
CIK:        0001520262
Form:       8-K
Filed at:   2023-12-14T23:59:59+00:00
Accession:  0000950170-23-070190
Event type: m_and_a
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alkermes sells Athlone facility to Novo Nordisk for $92.5M; 400 employees to transfer
--------------------------------------------------------------------------------

- Asset sale of Athlone development and manufacturing facility for $92.5M cash; expected to close mid-2024.
- Approximately 400 Alkermes employees at Athlone will transfer to Novo Nordisk upon closing.
- Alkermes to enter subcontracting arrangements to continue certain work at facility through end of 2025; deal expected to be cost-neutral over that period.
- Alkermes retains all royalty revenues from products currently manufactured at Athlone; continues producing VIVITROL, ARISTADA, LYBALVI at Wilmington, OH.
- CEO Richard Pops: transaction expected to drive operational efficiencies and enhance profitability as Alkermes focuses on pure-play neuroscience.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1520262/000095017023070190/0000950170-23-070190-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1520262/000095017023070190/alks-20231213.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-070190

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer